Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Assets (2016 - 2025)

Historic Assets for Myriad Genetics (MYGN) over the last 16 years, with Q3 2025 value amounting to $728.1 million.

  • Myriad Genetics' Assets fell 3266.44% to $728.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $728.1 million, marking a year-over-year decrease of 3266.44%. This contributed to the annual value of $1.0 billion for FY2024, which is 1037.07% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Assets is $728.1 million, which was down 3266.44% from $677.3 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Assets high stood at $1.4 billion for Q2 2021, and its period low was $677.3 million during Q2 2025.
  • Moreover, its 5-year median value for Assets was $1.2 billion (2023), whereas its average is $1.1 billion.
  • In the last 5 years, Myriad Genetics' Assets tumbled by 190.05% in 2023 and then tumbled by 3758.18% in 2025.
  • Myriad Genetics' Assets (Quarter) stood at $1.3 billion in 2021, then dropped by 9.24% to $1.2 billion in 2022, then fell by 4.35% to $1.1 billion in 2023, then decreased by 10.37% to $1.0 billion in 2024, then dropped by 29.15% to $728.1 million in 2025.
  • Its Assets stands at $728.1 million for Q3 2025, versus $677.3 million for Q2 2025 and $1.0 billion for Q1 2025.